Literature DB >> 3258308

Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid.

Y Lu1, J Han, K J Scanlon.   

Abstract

In this study, A2780 human ovarian carcinoma cells were grown in folinic acid in contrast to folic acid, and the molecular and biochemical properties of cisplatin-resistant A2780 cells were analyzed for changes in the dTMP synthase cycle. At concentrations of folinic acid that were optimal for cell growth (10(-8) M), the ED50 for cisplatin was 2.5 and 43 microM in the A2780S and A2780DDP cells, respectively. Resistance to cisplatin was associated with a 2-fold cross-resistance to 5-fluorodeoxyuridine and 5-fluorouracil as well as a 3-fold increase in both dTMP synthase activity and mRNA. The ED50 for methotrexate was similar in both A2780S and A2780DDP cells (1.2 microM). When both the A2780S and A2780DDP cells were grown in folinic acid, there was no significant difference in the level of dihydrofolate reductase activity. This data would suggest that cisplatin resistance is associated with changes in folate metabolism.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258308

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  E3 ubiquitin ligase HOIP attenuates apoptotic cell death induced by cisplatin.

Authors:  Craig MacKay; Eilís Carroll; Adel F M Ibrahim; Amit Garg; Gareth J Inman; Ronald T Hay; Arno F Alpi
Journal:  Cancer Res       Date:  2014-03-31       Impact factor: 12.701

2.  The role of folates in the development of methotrexate resistance in human leukemia cell line K562.

Authors:  H Miyachi; Y Takemura; Y Ando; K J Scanlon
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.

Authors:  Andries M Bergman; Auke D Adema; Jan Balzarini; Skjalg Bruheim; Iduna Fichtner; Paul Noordhuis; Oystein Fodstad; Finn Myhren; Marit L Sandvold; Hans R Hendriks; Godefridus J Peters
Journal:  Invest New Drugs       Date:  2010-01-12       Impact factor: 3.850

4.  Cytotoxicity of sphingoid marine compound analogs in mono- and multilayered solid tumor cell cultures.

Authors:  José M Padrón; Godefridus J Peters
Journal:  Invest New Drugs       Date:  2006-05       Impact factor: 3.651

5.  Knock-down of 25 kDa subunit of cleavage factor Im in Hela cells alters alternative polyadenylation within 3'-UTRs.

Authors:  Tomohiro Kubo; Tadashi Wada; Yuki Yamaguchi; Akira Shimizu; Hiroshi Handa
Journal:  Nucleic Acids Res       Date:  2006-11-10       Impact factor: 16.971

6.  Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines.

Authors:  F Ottone; S Miotti; C Bottini; M Bagnoli; P Perego; M I Colnaghi; S Ménard
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.

Authors:  C J van Moorsel; H M Pinedo; G Veerman; A M Bergman; C M Kuiper; J B Vermorken; W J van der Vijgh; G J Peters
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

8.  Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer.

Authors:  G Smith; M T H Ng; L Shepherd; C S Herrington; C Gourley; M J Ferguson; C R Wolf
Journal:  Br J Cancer       Date:  2012-09-18       Impact factor: 7.640

9.  Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; T Morikage; Y Fujiwara; N Saijo
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

10.  Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer.

Authors:  A A van Zweeden; C J van Groeningen; R J Honeywell; E Giovannetti; R Ruijter; C H Smorenburg; G Giaccone; H M W Verheul; G J Peters; Hans J van der Vliet
Journal:  Cancer Chemother Pharmacol       Date:  2018-04-25       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.